Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · MA · Jan 11, 2010 → Oct 21, 2026
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:20 AM ET · SEC enforcement last checked: Oct 24, 2026, 2:39 AM ET
Jonathan Fleming is listed as an executive officer and director on 31 SEC Form D filings by 15 issuers between Jan 2010 and Oct 2026. Largest by amount reported sold: Radius Health, Inc. (Cambridge, MA — pharmaceuticals — 2011; $126.9M reported sold to 36 investors), Greenlight Biosciences Inc. (Medford, MA — other technology — 2013–2017; $102.5M reported sold to 19 investors), SQZ Biotechnologies Co (Watertown, MA — biotechnology — 2015–2020; $71.3M reported sold to 48 investors), Q-State Holdings, Inc. (Cambridge, MA — biotechnology — 2018; $64.8M reported sold to 51 investors), QurAlis Corp (Cambridge, MA — pharmaceuticals — 2020; $60M reported sold to 27 investors) and 10 more (all listed below).
What this means That is a lot of deals — 15 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $507.8M sold in total.
Listed alongside Amy Schulman (7 shared filings), Armon Sharei, Ph.D. (6 shared filings), Klavs F. Jensen, Ph.D. (6 shared filings), Andrey Zarur (4 shared filings), Charles Cooney (4 shared filings) and 116 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.
The issuers belong to 2 sponsor groups: Greenlight (2 issuers, $111.3M reported sold, 2013–2020) and Q State (2 issuers, $23.2M reported sold, 2018–2020).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 9 bankruptcy cases matching the name listed in Key records below.
What this means 9 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 31 public filings for Jonathan Fleming and found 19 differences, 2 worth asking the sponsor about: Paid seller listed without a CRD number: U.S. Boston Capital Corporation; 8 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Jonathan Fleming has not run yet — it is #1,306 of 49,456 in line; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:20 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (checked Oct 24, 2026) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET
SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 2:39 AM ET.
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
9 cases: 2 open, 7 closed (disposition not in docket feed)
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:20 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
19 differences found between the filings for Jonathan Fleming — 2 worth asking about (compared 31 filings on Oct 24, 2026)
United States Bankruptcy Court, D. Massachusetts docket "DiLuigi Brand, Inc." filed Dec 6, 1991, closed Nov 7, 1996. Michael DiLuigi (listed on the same filings) is listed as Debtor ("DiLuigi Brand, Inc."). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, W.D. Pennsylvania docket "Garry A. Nicholson and Bobbie A. Nicholson" filed Jul 12, 1994, closed Nov 25, 1994. Garry A. Nicholson (listed on the same filings) is listed as Debtor ("Garry A. Nicholson and Bobbie A. Nicholson"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Jun 25, 2019 Form D reports $428,368 sold and $103,450 of the proceeds used for payments to officers, directors or promoters (marked as an estimate). Issuer's note: "Repayment of promissory note.".
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
The Feb 4, 2010 Form D/A reports $12,755,376 sold and $2,500,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate).
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
The Jan 11, 2010 Form D reports $12,500,000 sold and $2,500,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate).
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
EnClear Therapies, Inc. (last filing Mar 1, 2024; $718,331 sold of $1,999,996); Rib-X Pharmaceuticals, Inc. (last filing Nov 30, 2012; $18,686,500 sold of $67,500,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
U.S. Boston Capital Corporation is listed as receiving sales compensation on 1 filing (Feb 22, 2010) with no FINRA CRD number given.
What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.
Form D filed 165 days after the first sale — SQZ Biotechnologies Co · Form D filed 563 days after the first sale — SQZ Biotechnologies Co · Form D filed 17 days after the first sale — QurAlis Corp · Form D filed 16 days after the first sale — Continuus Pharmaceuticals, Inc. · Form D filed 21 days after the first sale — Q-State Holdings, Inc. · and 3 more
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — Diceros Therapeutics, Inc. (latest filing Aug 5, 2024) · No amendment in the last 12 months on an offering that may still be open — EnClear Therapies, Inc. (latest filing Mar 1, 2024) · No amendment in the last 12 months on an offering that may still be open — Aquacultural Research Corp (latest filing Jan 12, 2024) · No amendment in the last 12 months on an offering that may still be open — SQZ Biotechnologies Co (latest filing Jun 1, 2020) · No amendment in the last 12 months on an offering that may still be open — QurAlis Corp (latest filing May 18, 2020) · and 9 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
The Jun 25, 2019 filing lists Jonathan Fleming as director; the Jan 12, 2024 Form D lists executive officer, director.
What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.
Offering amount changed between filings — Diceros Therapeutics, Inc. · Offering amount changed between filings — SQZ Biotechnologies Co · Offering amount changed between filings — SQZ Biotechnologies Co · Offering amount changed between filings — Greenlight Biosciences Inc.
What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.
"Biotechnology" (Aug 9, 2013 to Jun 16, 2015); then "Other Technology" (Sep 14, 2017).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"No Revenues" (Jun 25, 2014); then "Decline to Disclose" (Sep 11, 2019).
What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.
"$1,000,001 - $5,000,000" (Feb 22, 2010); then "Decline to Disclose" (Jan 6, 2014).
What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.
This page covers filings where the address state is MA. A separate record, "Jonathan Fleming" with address state CA, is listed on 2 filings — most recently by Onc.ai, Inc. (Dec 2, 2020). Both records have filings in the same period (Jul 1, 2013 to Dec 2, 2020).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
This page covers filings where the address state is MA. A separate record, "Jonathan J. Fleming" with address state OH, is listed on 2 filings — most recently by Laboratory Partners Inc (May 10, 2010). Both records have filings in the same period (Jan 11, 2010 to May 10, 2010).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
The people listed on the Jun 25, 2014 filing give Boston, MA; on the Sep 11, 2019 filing they give Woburn, MA.
What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.
The people listed on the Oct 4, 2016 filing give Boston, MA; on the Dec 1, 2016 filing they give Watertown, MA.
What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.
The people listed on the Aug 9, 2013 filing give Waltham, MA; on the Dec 20, 2013 filing they give Medford, MA. The address now on file (200 Boston Avenue, Suite 3100, Medford, MA) is a registered-agent or shared-office address used by 8 issuers.
What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
2 of 25 offerings report sales commissions totalling $1,237,368; 0 report finder's fees; 5 report proceeds to related persons totalling $4,316,487. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Oct 21, 2026 D Quiver Holdings Inc. File 021-601971 | $0 | $0 | $0 None, other than ordinary compensation and director fees. | None listed on this filing | EDGAR ↗ |
| Aug 5, 2024 D/A Diceros Therapeutics, Inc. File 021-460347 | $0 | $0 | $1,038,035 | None listed on this filing | EDGAR ↗ |
| Mar 1, 2024 D EnClear Therapies, Inc. File 021-506508 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 12, 2024 D Aquacultural Research Corp File 021-502312 | $0 | $0 | $2 (est.) Repayment of convertible notes. | None listed on this filing | EDGAR ↗ |
| Jun 1, 2020 D SQZ Biotechnologies Co File 021-368023 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 18, 2020 D QurAlis Corp File 021-367164 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 25, 2019 D SQZ Biotechnologies Co File 021-354117 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 11, 2019 D Continuus Pharmaceuticals, Inc. File 021-348478 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 25, 2019 D Aquacultural Research Corp File 021-342750 | $0 | $0 | $103,450 (est.) Repayment of promissory note. | None listed on this filing | EDGAR ↗ |
| Oct 25, 2018 D Q-State Holdings, Inc. File 021-324311 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 14, 2017 D Greenlight Biosciences Inc. File 021-294749 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 1, 2016 D/A SQZ Biotechnologies Co File 021-271785 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 27, 2015 D Aquacultural Research Corp File 021-246520 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 28, 2015 D/A SQZ Biotechnologies Co File 021-242788 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 16, 2015 D Greenlight Biosciences Inc. File 021-241858 | $0 | $0 | $675,000 (est.) The Issuer expects to pay approximately $675,000 of the gross proceeds to related persons as compensation, including benefits, over the course of one year. | None listed on this filing | EDGAR ↗ |
| Jun 25, 2014 D Continuus Pharmaceuticals, Inc. File 021-219828 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 6, 2014 D RAILRUNNER NA INC File 021-209333 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 20, 2013 D/A Greenlight Biosciences Inc. File 021-201107 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 6, 2012 D/A AVAXIA BIOLOGICS, Inc File 021-168953 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 31, 2011 D Radius Health, Inc. File 021-160578 | $434,868 | $0 | $0 | Leerink Swann LLC BrokerCheck CRD 39011 ↗ via Leerinks Swann LLC (CRD 39011 ↗) | EDGAR ↗ |
| May 31, 2011 D Radius Health, Inc. File 021-160580 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jun 10, 2010 D Rib-X Pharmaceuticals, Inc. File 021-143283 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 14, 2010 D HYDROCISION INC File 021-140572 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 22, 2010 D RAILRUNNER NA INC File 021-76309 | $802,500 (est.) | $0 | $0 | U.S. Boston Capital Corporation no CRD number reported | EDGAR ↗ |
| Feb 4, 2010 D/A MOLECULAR BIOMETRICS INC File 021-123566 | $0 | $0 | $2,500,000 (est.) | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Jonathan Fleming on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $3M from 4 investors as of the latest filing. Jonathan is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $12.6M from 13 investors (70% of the $18.1M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $718K from 8 investors (36% of the $2M target) as of the latest filing. Jonathan is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $1.63M from 17 investors (100% of the $1.5M target) as of the latest filing. Jonathan is listed as executive officer, director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $71.3M from 48 investors (100% of the $70.2M target) as of the latest filing. Jonathan is listed as director on 6 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $60M from 27 investors (100% of the $60M target) as of the latest filing. Jonathan is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $5M from 20 investors (100% of the $5M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $64.8M from 51 investors (97% of the $66.6M target) as of the latest filing. Jonathan is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $102.5M from 19 investors (100% of the $18M target) as of the latest filing. Jonathan is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $13.4M from 10 investors (100% of the $6.08M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $11.5M from 164 investors (100% of the $4.46M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $126.9M from 36 investors (100% of the $126.9M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $18.7M from 16 investors (100% of the $15M target) as of the latest filing. Jonathan is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $3.02M from 12 investors (100% of the $700K target) as of the latest filing. Jonathan is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Raised $12.8M from 16 investors (75% of the $17M target) as of the latest filing. Jonathan is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Amy Schulman is on 20 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
David Furneaux is on 9 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Andrey Zarur is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Charles Cooney is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Eric Moessinger is on 8 issuers in total — a repeat sponsor. Their page lists every one.
Robert Ackerman is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Garry A. Nicholson is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Kurt Graves is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Ansbert Gadicke is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Peter Barrett is on 12 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
Listed on the same filings as Jonathan Fleming. Their page shows their other deals.
One team, 2 deal companies. Jonathan Fleming is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan Fleming.
One team, 2 deal companies. Jonathan Fleming is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Jonathan Fleming.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
None of the 15 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Jonathan Fleming by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 15 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Jonathan Fleming is listed on: none on file. No website or social profile named in Q-State Holdings, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #219,778 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Jonathan Fleming appears on a new Form D, or when a court case or SEC action is matched to them. See plans →
